Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 1998

View Archived Issues

Company Profile: Arena

Bis-imide antitumor agents developed at ADIR

Na+/H+ exchange inhibitors claimed for ischemic and other disorders by Hoechst

Hemosol: Q1 1998 highlights

Development status of HMR-3647

IntraBiotics obtains certain rights to ramoplanin

Preclinical and phase I results reported for MS-325

FDA issues nonapprovable letter for Novastan

Phase II clinical trial initiated for Neotrofin

Diatide reports preliminary phase III clinical results for P829

Wyeth-Lederle acquires Apollon

Roche presents series with potent activity against HSV thymidine kinase

Neuraminic acid derivatives claimed by Sankyo for influenza

Banyu describes antimuscarinic piperidines with bronchodilating effects

VP22 provides intercellular delivery of functional p53 protein

Palatin to meet with FDA to discuss LeuTech in late July

Bexxar: encouraging interim phase III data reported

Zenapax shows promise in pediatric kidney transplantation

Myotrophin declared "potentially approvable" by FDA

T Cell and Virus Research Institute sign merger agreement

Pharmacokinetic profile of GTS-21 studied in rats after parenteral, oral dosing

FDA issues approvable letter for Roche's novel antiobesity Rx

FDA clears Novartis to market Simulect for use in renal transplantation

RPR scientists identify new nonpeptide RANTES antagonist

CombiChem achieves milestone in collaboration with Teijin

Microbial product acts as ergosterol biosynthesis inhibitor in in vitro screen

Cardioprotective effects of MET-88, a carnitine biosynthesis inhibitor

Connetics and Genentech expand Actimmune collaboration

TheraTech and Astra announce collaborative development of new pain medication